Metabolic Syndrome and Autoimmune Diabetes: Action LADA 3
| Autor: | Hawa, M. I., Thivolet, C., Mauricio, D., Alemanno, I., Cipponeri, E., Collier, D., Hunter, S., Buzzetti, Raffaella, De Leiva, A., Pozzilli, P., Leslie, Rd, Behalf Of The Action Lada Group, O. N. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Latent autoimmune diabetes of adults
Adult Male medicine.medical_specialty Cardiovascular and Metabolic Risk Urban Population Endocrinology Diabetes and Metabolism medicine.medical_treatment Population Blood Pressure Type 2 diabetes Insulin resistance Risk Factors Diabetes mellitus Internal medicine Internal Medicine medicine Body Size Humans Age of Onset education Triglycerides Aged Advanced and Specialized Nursing Metabolic Syndrome education.field_of_study Type 1 diabetes Sex Characteristics business.industry Insulin Cholesterol HDL Middle Aged medicine.disease Europe Endocrinology Cross-Sectional Studies Diabetes Mellitus Type 1 Diabetes Mellitus Type 2 Female Metabolic syndrome business Biomarkers |
| Zdroj: | Diabetes Care DIABETES CARE r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau instname |
| ISSN: | 1935-5548 0149-5992 |
| Popis: | OBJECTIVE—The purpose of this study was to estimate whether prevalence of metabolic syndrome in adult European diabetic patients is associated with type of diabetes. RESEARCH DESIGN AND METHODS—A consecutive series of patients attending hospital-based diabetes clinics were assessed for the frequency of metabolic syndrome and compared with population-based control subjects as part of the Action LADA study. In total, 2,011 subjects (aged 30–70 years) were studied, including 1,247 patients with recent-onset type 2 diabetes without glutamic acid decarboxylase autoantibodies (GADAs), 117 non–insulin-requiring patients with GADAs who had not received insulin therapy for at least 6 months after diagnosis (designated latent autoimmune diabetes of adults [LADA]), 288 type 1 diabetic patients, and 359 normal subjects. RESULTS—Frequency of metabolic syndrome was significantly different in patients with type 1 diabetes (31.9%) and LADA (41.9%) (P = 0.015) and in both conditions was less frequent than in type 2 diabetic patients (88.8%) (P < 0.0001 for each). Eliminating glucose as a variable, the prevalence of metabolic syndrome was similar in patients with autoimmune diabetes (type 1 diabetes and/or LADA) (17.3%) and control subjects (23.7%) but remained more common in type 2 diabetic patients (47.8%) (P = 0.001 for all groups). In both type 1 diabetic patients and those with LADA, individual components of metabolic syndrome were similar but less common than in type 2 diabetic patients (P < 0.0001 for each). CONCLUSIONS—The prevalence of metabolic syndrome is significantly higher in type 2 diabetic patients than in patients with LADA or adults with type 1 diabetes. Excluding glucose as a variable, metabolic syndrome is not more prevalent in patients with autoimmune diabetes than in control subjects. Metabolic syndrome is not a characteristic of autoimmune diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|